WillItSurvive
Medical technology and health companies · United States

Pacific Biosciences

pacb.com ↗

Maker of long-read DNA sequencing machines used in genomics research and clinical labs.

Losing its protection
Assessed 22 July 2026 · Evidence as of 22 July 2026
The structural protection is eroding.
On the recordSince 22 July 2026 · Checkable from Q3 2026 · Every call on the record Checkpoint: Two quarters of SPRQ-Nx chemistry sales data needed to show revenue reacceleration
The call

PacBio's sequencing technology still works and clinics still buy it, but the company is running out of cash and time faster than it is growing.

Pacific Biosciences sells machines that read long stretches of DNA quickly and accurately, using a patented technology that competitors like Oxford Nanopore cannot easily copy. The real problem is not the technology, but the business: Oxford Nanopore is growing four times faster, PacBio is losing money every quarter, and the company is so financially weak it risks being delisted from the stock market. The one thing that could turn this around is if their new cheaper sequencing system, launched in mid-2026, starts selling well enough to generate revenue quickly. If that does not happen within a few quarters, even the strong technology may not be enough to save the company.

Why
01
AI pressure: Google DeepConsensus/AlphaEvolve. AI models actually improve PacBio's HiFi read accuracy rather than replacing it, but that edge is easy for rivals to copy too. Could AI do the core job? Unlikely.
02
Bigger players: Oxford Nanopore. Nanopore grows sales 21 to 25 percent a year while PacBio limps at 4 percent, pulling long-read customers away. Could a giant copy it? Probably.
03
What protects it. Locked-in hospitals and labs running Part 11 clinical workflows on PacBio's Revio machines are costly to switch.
What would change this call
PacBio reports two consecutive quarters of SPRQ-Nx driven revenue growth above 10 percent. Would show the new chemistry is winning back growth and slowing customer defection to Oxford Nanopore.
PacBio stock price approaches or breaches the $1.00 Nasdaq minimum bid threshold. Would show financial distress deep enough to threaten delisting and equity survival.
Oxford Nanopore's reported growth rate versus PacBio's widens further in coming quarterly results. Would confirm PacBio is losing further ground to Oxford Nanopore in long read sequencing.
Key numbers
  • FY2025 revenue $160.0M, up only 4% (2026-02-12)
  • Stock near $1.39 to $1.65, close to $1 delisting floor (2026-07-22)
  • Cash burn about $126M over trailing twelve months (2026-02-02)
Named risks
  • Sustained cash burn of ~$126M TTM against a ~$450M market cap threatens solvency. Severity: high
  • Stock trading near historic lows raises Nasdaq delisting exposure under tightened 2026 rules. Severity: medium
  • Active securities-law investigation tied to 2024 guidance miss could result in litigation costs. Severity: medium
  • Revenue growth of only 4% vs Oxford Nanopore's 24% widens competitive gap in core long-read market. Severity: high
  • 34.8% headcount reduction since 2023 signals ongoing organizational instability. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Oxford Nanoporegaining onONT revenue $295M TTM growing 24.2% vs PacBio $160.0M growing 4% in FY2025 (2026-03-02)
IlluminacontestingIllumina $4.34B FY2025 revenue, pursuing TruPath long-read workaround; blocked $1.2B PacBio buyout 2018-2020
BGI/MGIgaining onPacBio APAC revenue fell 16% YoY in Q1 2026 partly on Chinese price competition
Questions people ask
Is Pacific Biosciences profitable in 2026?
No. PacBio posted a Q1 2026 non-GAAP net loss of $0.12 per share and a $37.6M non-GAAP net loss in Q4 2025 alone, while FY2025 revenue grew just 4% to $160.0M, as reported 2026-05-07 and 2026-02-12.
Who owns Pacific Biosciences?
PacBio is publicly traded on Nasdaq under PACB with no controlling parent. Its market cap was approximately $435 to $464 million as of 2026-07-22, with shares trading around $1.39 to $1.65, far below its all-time high of $53.69.
Is PacBio losing to Oxford Nanopore?
Yes. Oxford Nanopore's FY2025 revenue reached about $295M TTM growing 24.2% and now exceeds PacBio's $160.0M FY2025 revenue, which grew only 4%, per a 2026-03-02 earnings report, putting PacBio in a distant number two long-read position.
Could AI replace Pacific Biosciences?
Unlikely to replace it outright. Google's DeepConsensus AI, refined with AlphaEvolve, has processed over 75% of all bases PacBio has ever produced (as of 2026-04-30), but AI enhances PacBio's basecalling rather than substituting for its physical SMRT chemistry sequencing hardware.
Is Pacific Biosciences stock at risk of delisting?
It is a live concern. PACB traded around $1.39 to $1.65 as of 2026-07-22, above Nasdaq's tightened $0.10 accelerated-delisting threshold effective 2026-01-19, but the stock is down over 90% from its all-time high, leaving little buffer.
Did Illumina try to acquire Pacific Biosciences?
Yes. Illumina attempted a $1.2 billion acquisition of PacBio in 2018-2019, which the FTC sued to block; the deal was abandoned in January 2020 and Illumina paid PacBio a $98 million termination fee.
Timeline
  • 2026-05-26SPRQ-Nx chemistry launched commercially worldwide, $345 per-genome list price
  • 2026-05-12PACB stock fell 14.2% in one session after Q1 2026 revenue miss
  • 2026-05-08Q1 2026 revenue $37.2M flat YoY, FY2026 guidance cut to $165-175M
  • 2026-03-31Levi & Korsinsky announces active securities-law investigation into PacBio
  • 2026-03-06Binding term sheet settles Personal Genomics Taiwan patent litigation; CAO Farmer resigns
  • 2026-02-12FY2025 results: revenue $160.0M, up 4% YoY
  • 2026-02-02PacBio completes sale of short-read (Onso) assets to Illumina for $48.1M
  • 2025-10-14PacBio announces SPRQ-Nx chemistry targeting sub-$300 genome cost
  • 2025-04-09PacBio cuts ~80 current and 40 planned positions, ~$45-50M savings
  • 2024-05-14PacBio lays off ~195 employees (25% of staff), closes San Diego office
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources